Endogenic D-Bol (Dianabol Injection)

What is methanedienone?

Methandienone (chemically 17α-methyl-17β-hydroxy-androsta-1,4-dien-3-one) is a synthetic anabolic-androgenic steroid and belongs to the most historically familiar compounds in the class. Structurally, the molecule is based on testosterone with two modifications: an extra double bond between carbon-1 and carbon-2 in the A-ring and a methyl group in the 17α position. The first change lowers the affinity for the aromatase enzyme and leads to the formation of methylestradiol instead of estradiol — a weaker estrogenic metabolite. The second modification, the 17α-alkylation, blocks the rapid inactivation in the liver and enables oral activity, but at the same time provides a hepatotoxic profile not seen in non-alkylated molecules.

The substance was developed by John Ziegler in collaboration with Ciba in the late 1950s and was introduced to the American market in 1958 under the trade name Dianabol. The original clinical indication included cachexia, burns, postoperative convalescence and some forms of general malnutrition. After the FDA withdrew its approval in 1985, methandienone has been mainly manufactured by generic producers in other countries, and the oral form remains one of the most widely used anabolic steroids.

The injection form is uncommon on the commercial market but exists as a pharmaceutical variation where the same molecule is dissolved in an oil-based or water-based suspension medium. The 17α-alkylated structure remains regardless of the route of administration, which means that hepatotoxic properties persist even after injection. The half-life for oral use is around 3–6 hours; the injection form gives a slightly extended profile depending on the vehicle.

How does methane dienone work?

After administration, methandienone circulates in the blood and binds to the androgen receptor (AR) in target cells with good affinity, albeit lower than free testosterone. The formed ligand-receptor complex is moved to the cell nucleus and directs the transcription of genes linked to protein synthesis and nitrogen balance. The ratio between anabolic and androgenic activity is stated in classic literature to be approximately 210:60 with testosterone as a reference 100:100 — significantly increased anabolic component and lower androgenic character.

The extra double bond in the A ring gives methandienone some substrate activity at the aromatase enzyme, but the end product is methylestradiol rather than estradiol. Methylestradiol has a lower affinity to the estrogen receptor than the endogenous variant, which means that estrogenic side effects occur but in a different profile than with testosterone. The molecule is resistant to 5α-reductase because the extra double bond changes the reactivity of the A ring.

The 17α-alkylation is central to the pharmacology of the molecule. It blocks the first-pass metabolism in the liver and keeps the substance active in the circulation. At the same time, the liver's enzyme system and hepatocytes are directly burdened, which in case of prolonged exposure can cause elevated transaminases, cholestasis and, in rare cases, more serious liver damage such as peliosis hepatis. When injected, the substance does indeed bypass the first passage on the first passage, but the molecule recirculates through the liver on each passage through the systemic circulation, which means that the hepatotoxic load remains.

What can methane dienone potentially affect?

In pharmacological literature from decades of clinical and extraclinical use, several physiological systems in which methandienone shows imprints reappear:

• Muscle tissue — strong activation of AR in myocytes with pronounced increase in protein synthesis, nitrogen balance and glycogen storage in muscle cells.

• Water balance and electrolytes — the molecule causes rapid and noticeable water retention with accompanying weight gain, a phenomenon linked to methylestradiol and sodium retention.

• Erythropoiesis — stimulation of renal EPO production raises hematocrit and hemoglobin concentration.

• Estrogen metabolism — partial aromatization to methylestradiol gives estrogenic activity with lower receptor affinity than natural estradiol.

• The hypothalamic-pituitary-gonadal axis (HPG) — rapid onset and strong suppression of GnRH as well as LH and FSH with consequent downregulation of endogenous testosterone production.

• Hepatic and protein metabolism — direct effect on hepatocytes via the 17α-alkylation as well as altered expression of liver-produced proteins such as SHBG and fibrinogen.

Potential Side Effects of Methandienone

The side effect profile for metandienone, regardless of route of administration, is characterized by the combination of 17α-alkylation, partial aromatization to methylestradiol and associated estrogenic activity. Hepatotoxic properties are central to the risk picture because the molecule recirculates through the liver even upon injection. The rapid effect on water balance produces characteristic subcutaneous retention which normally subsides upon discontinuation.

• Hepatological — elevated transaminases, cholestatic hepatitis, disturbed bilirubin metabolism and with prolonged exposure risk of peliosis hepatis and in rare cases hepatocellular adenomas. The effect persists after injection because the 17α-alkylation is not affected by the route of administration.

• Estrogen-related — gynecomastia, water retention, edema and increased blood pressure due to methylestradiol and sodium retention.

• Hormonal changes—pronounced suppression of the HPG axis with decreased endogenous testosterone production, shrunken testes, and impaired spermatogenesis.

• Cardiovascular effects — markedly unfavorable shift in the lipid profile (pronounced lowering of HDL, raised LDL), increased blood pressure and, in the long term, risk of left ventricular hypertrophy.

• Hematological — rising hematocrit which, at extreme values, increases blood viscosity and thromboembolic risk.

• Androgenic — acne, seborrhea, oily skin and accelerated male pattern baldness in genetically predisposed individuals.

• Psychological — mood swings, irritability, increased aggression, sleep disturbances and, in the withdrawal phase, depressed mood.

• In women — pronounced risk of virilization symptoms: voice deepening, hirsutism, clitoral hypertrophy and menstrual disorders. Some changes are permanent.

The overall side effect picture of metandienone — hepatotoxic load, estrogenic and androgenic influence, cardiovascular shifts — means that clinical use requires close follow-up with laboratory controls (liver enzymes, lipid status, blood count, hormone panel) and a realistic assessment of the risk-benefit balance.